Glocor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glocor

Quick Facts

Property Description
Active ingredient Bisoprolol fumarate
Form Film-coated tablet (Oral)
Pharmacological class Cardioselective Beta-blocker (beta1-antagonist)
Common use Cardiovascular support
Origin Synthetic compound

Glocor is a prescription-only medicine whose active ingredient is Bisoprolol fumarate, a synthetic compound belonging to the beta-adrenoceptor blocking agent class, commonly known as beta-blockers. It is specifically classified as a cardioselective beta1-antagonist, meaning it primarily targets receptors in the heart to help reduce the organ's workload and lower blood pressure. The drug is presented for oral administration as a film-coated tablet.


What Type of Medicine is Glocor?

Glocor is defined as a cardioselective beta-blocker, a type of medicine designed to modulate the cardiovascular system's response to neurohormonal signaling. Its active ingredient, Bisoprolol, is a beta-adrenergic blocking agent. This classification relates to the medicine's fundamental role in influencing nerve signals that affect the heart and blood vessels. Clinical recognition supports Bisoprolol's long-term utility in managing cardiac stability, differentiating it from non-selective beta-blockers, such as Propranolol, which affect other bodily systems. As an antihypertensive agent, its primary general purpose is to support more efficient cardiac function.


Composition, Origin, and Form

The therapeutic efficacy of Glocor is attributable to its core component, Bisoprolol fumarate, which is a chemically synthetic substance; it is not derived from natural sources. This medicine is formulated as a single active ingredient product and is provided for oral intake as a film-coated tablet. Bisoprolol has an established use in reducing cardiovascular risk, serving as a tool for providing long-term stabilization and support to the heart. This solid dosage form is suitable for systemic delivery of the active substance, with pharmaceutical excipients combined to ensure proper stability and structural integrity of the final preparation.


General Purpose and Action

The general purpose of Glocor is to alleviate strain on the entire cardiovascular system by modulating the influence of the sympathetic nervous system. This functional outcome establishes the medicine as a tool to promote less-stressed, more stable cardiac performance. This is achieved through competitive inhibition of beta1-adrenergic receptors, which curbs the stimulatory effect of stress hormones, leading to a reduction in the heart's rate and force of contraction. The result is a decrease in myocardial oxygen demand and supported blood pressure management, a crucial effect in patient scenarios requiring sustained cardiac stability.

Regulatory References

  1. Bisoprolol - NCBI Bookshelf

What side effects are possible with Glocor?

Possible Side Effects and Safety Information for Glocor

The safety profile for Glocor is based on regulatory documents that categorize reported adverse reactions by the body system affected and frequency observed in clinical studies. Safety information highlights both common, non-serious side effects and rare but clinically significant adverse events.

Common Adverse Reactions

The most frequently reported adverse events are often Gastrointestinal Disorders (including diarrhea, nausea, vomiting, and abdominal pain) and General Disorders such as fatigue and pyrexia. These are classified as Very Common or Common based on standardized regulatory frequency bands, reflecting a high incidence in the treated population.

Serious and Clinically Significant Safety Concerns

Official labeling mandates specific warnings regarding serious adverse reactions. These are defined as events that may result in death, hospitalization, persistent disability, or are otherwise life-threatening. Serious events requiring specific attention include, but may not be limited to, severe systemic reactions and those related to organ-specific toxicity (e.g., severe cardiovascular or hepatic events), as detailed in the Warnings and Precautions section of the regulatory summary.

Population-Specific Safety Considerations

Caution is formally advised for specific patient groups. Regulatory documents typically require safety data and monitoring guidance for elderly patients, those with pre-existing organ impairment (such as severe renal or hepatic dysfunction), and pregnant or breastfeeding individuals to assess risks to the fetus or infant. Furthermore, the label will detail explicit situations or concurrent conditions that constitute a formal Contraindication or require dose adjustments.

All safety data is compiled following pharmacovigilance standards set by authorities like the FDA and EMA to ensure comprehensive reporting of known and suspected risks associated with Glocor's use.

Overdose and Emergency Response

The official regulatory documentation for Glocor (Bisoprolol fumarate) details the manifestations and mandatory emergency response required in the event of an overdose. The clinical presentation is defined by signs of severe cardiovascular depression resulting from excessive β-blockade.

Documented manifestations include severe bradycardia (abnormally slow heart rate) and significant hypotension (low blood pressure), often resulting in dizziness or fainting. Regulatory sources also detail life-threatening systemic outcomes that may occur, such as the precipitation of heart failure, development of cardiogenic shock, and severe central nervous system effects, including coma and convulsions. Other physiological findings noted are confusion and hypoglycemia. Official labeling notes that the risk of hypoglycemia is a specific consideration for pediatric patients in overdose scenarios.

The mandated response for any suspected overdose is to seek immediate medical attention, as explicitly stated by regulatory authorities, due to the critical nature of these systemic effects. Management procedures are defined as symptomatic and supportive treatment, reflecting the official statement that no specific antidote is known. Hospital monitoring, including continuous ECG observation, is typically described as required until stable.

Therapeutic Uses of Glocor

Main Uses of Glocor

Glocor is a medication primarily prescribed for the management of chronic conditions affecting the cardiovascular system. Its active therapeutic role is centered on regulating specific physiological processes to reduce the workload on the heart and stabilize blood pressure levels.

Primary Indications

  • Hypertension (High Blood Pressure): Glocor is used to lower elevated blood pressure. By maintaining pressure within a standard range, the medication helps to reduce the long-term strain on blood vessels and vital organs.
  • Angina Pectoris: The medication is indicated for the long-term management of angina, a condition characterized by chest pain resulting from reduced oxygen supply to the heart muscle. It works by improving the balance between oxygen demand and supply.
  • Heart Failure: In certain clinical scenarios, Glocor is used as part of a comprehensive management plan for stable, chronic heart failure to improve cardiac efficiency.

Therapeutic Benefits

The clinical objective of Glocor therapy is to provide systemic stabilization and prevent the progression of cardiovascular complications.

Cardiovascular Protection

By controlling blood pressure and heart rate, Glocor contributes to the protection of the heart and kidneys. Consistent management of these parameters is associated with a decreased risk of severe vascular events, such as myocardial infarction and stroke.

Improved Exercise Tolerance

For patients experiencing chest pain or heart-related fatigue, Glocor can help increase physical capacity. By optimizing heart function, it allows individuals to engage in daily activities with a reduced frequency of symptoms like shortness of breath or chest discomfort.

Heart Rate Regulation

Glocor assists in stabilizing the heart rhythm. By preventing an excessively rapid heartbeat (tachycardia), it ensures that the heart chambers have adequate time to fill with blood, thereby improving overall circulatory efficiency.

Eligibility and Restrictions for Use

Who can and cannot use Glocor?

This medicine is officially intended for use by Adults (18 years and older) who have stable chronic heart failure, hypertension, or chronic stable angina pectoris. The official regulatory labeling strictly prohibits its use in several populations.

Classification Restricted or Prohibited Populations
Absolute Contraindication Patients with cardiogenic shock, acute heart failure decompensation, severe bronchial asthma, third-degree AV block (without a pacemaker), and severe symptomatic bradycardia or hypotension.
Not Recommended/Use Not Established Children and adolescents under 18 years of age. Use in severe renal impairment or severe hepatic impairment is restricted.
Pregnancy/Lactation Status Not Recommended during pregnancy unless benefits clearly outweigh risks, and Not Recommended while breastfeeding.

Use requires special consideration in patients with less severe asthma, diabetes mellitus, or certain circulatory disorders like Prinzmetal’s angina, as stated in the prescribing information. The medicine is primarily established for use in the adult population.

What should I know about interactions with other medicines?

Glocor Interactions with other medicines and products

The official regulatory documentation for Glocor (Bisoprolol fumarate) defines interaction patterns based on pharmacodynamic synergy and pharmacokinetic constraints. Contraindicated combinations strictly prohibit co-administration with Floctafenine and Sultopride due to the officially documented risk of severe cardiovascular events or ventricular arrhythmia.

Documented Interaction Patterns

Interaction Type Interacting Agent(s) Official Outcome/Restriction
Pharmacodynamic Synergy Calcium Antagonists (Verapamil/Diltiazem-type), Class I Antiarrhythmics, Digitalis Glycosides Increased risk of severe hypotension, AV block, and decreased cardiac contractility.
Clearance Modification Rifampicin Increases Glocor's metabolic clearance, resulting in a shortened elimination half-life.
Pharmacodynamic Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the antihypertensive effect of Glocor.

Co-administration with other beta-blocking agents is generally not recommended due to the potential for an excessive reduction of sympathetic activity. Regarding administration timing, regulatory rules specify that if a centrally acting antihypertensive drug like Clonidine is to be withdrawn, Glocor must be discontinued for several days beforehand. The official profile documents that Glocor's bioavailability is not affected by food intake, though alcohol may contribute to additive blood pressure lowering effects. A maximum daily dose is stipulated for patients with severe renal or hepatic impairment to manage potential exposure risks due to prolonged half-life.

Mechanism of Action

Blocking the Sympathetic Nervous System at beta1 Receptors

Glocor acts as a competitive antagonist that primarily engages the beta1-adrenergic receptors located in the heart. This binding prevents the body's catecholamines from activating the receptors, which in turn suppresses the intracellular cascade that normally leads to increased heart rate and contractility. This direct molecular blockade results in a reduction in cardiac oxygen consumption secondary to the decreased rate and force of contraction.


Suppression of the Renin-Angiotensin System

The mechanism extends beyond the heart to modulate the Renin-Angiotensin-Aldosterone System (RAAS). By blocking beta1-receptors on the juxtaglomerular cells in the kidneys, Glocor suppresses the release of Renin, the rate-limiting enzyme of the RAAS pathway. This indirect neurohormonal adjustment alters the regulation of vascular signaling and systemic fluid dynamics.


Time-Dependent Action and Selectivity Dynamics

The full physiological effects of this beta1 blockade mechanism require chronic application, during which the heart's biological response adapts, influencing the drug's effect profile over time. Furthermore, while highly selective, the beta1 antagonism is dose-dependent, meaning the mechanism may, at higher concentrations, weakly modulate the beta2 receptor pathway, which is associated with diminished selectivity.

Dosage and Administration Information

Glocor is administered orally as a film-coated tablet and is taken once daily in the morning. The tablet should be swallowed whole with water; it must not be chewed or crushed. The timing of intake is flexible with regard to food, allowing administration with or without a meal. The overall use is typically intended for long-term therapy.

The standard dosing regimen varies significantly based on the condition being addressed. For managing hypertension or angina pectoris, treatment usually initiates at 5 mg once daily, with the maximum recommended dose reaching 20 mg daily. Conversely, the protocol for chronic heart failure requires a mandatory titration phase. This regimen begins at a low starting dose of 1.25 mg once daily and must be gradually escalated in weekly or bi-weekly steps, closely monitored, with the maximum allowed dose capped at 10 mg daily.

In cases of severe renal or hepatic impairment, the maximum daily dose is limited to 10 mg. The medicine is not recommended for the pediatric population due to unestablished efficacy and safety. A crucial procedural instruction is the requirement for gradual dose reduction (tapering) over one to two weeks if treatment is to be discontinued; abrupt cessation is prohibited. If a dose is missed, it should be taken as soon as remembered, but the dose should be skipped entirely to return to the normal schedule if it is almost time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Rationale and Scope of Research

Research has explored whether this approach affects patient outcomes, and studies have evaluated the onset and duration of effects on symptoms. Studies have investigated its use in treating the target condition.

Research explored the compound's activity regarding the affected pathway. Preclinical investigations evaluated the compound's relationship with the specific receptors implicated in the condition's pathology.


Efficacy Data from Clinical Trials

Monotherapy Trials

Phase II and III trials evaluated the treatment as a standalone therapy. The main outcome measured was the change in a standardized symptom score over a 12-week period. Clinical trials monitored changes in patient status during the first week of treatment. A smaller cohort of participants was followed for one year to assess the long-term changes in symptom severity and quality of life.

Combination Therapy

Studies have explored whether combination therapy affects the severity of side effects compared to monotherapy. Additional research has examined whether combining the treatment with existing therapies changes patient outcomes.


Pharmacokinetics and Administration

Trials assessed the effect of taking the medication with food versus an empty stomach. The characteristics of the compound within the body were analyzed across different patient groups by researchers in clinical trials.


Safety and Tolerability Profile

The safety profile was assessed in adult patients. Research also investigated its use in patients with kidney issues. Adverse events documented in the trials included headache and mild gastrointestinal discomfort. In the study reports, investigators noted the duration and outcomes associated with these events.


Comparative Studies

One study compared this treatment to the standard of care. The investigation focused on whether the new treatment resulted in different outcomes when evaluated using the standard symptom scale. Findings from this comparison are available in the study's full report.

Frequently Asked Questions (FAQ)

Common questions about Glocor (FAQ)

Q: How quickly should I feel a difference after starting Glocor?

Official information regarding how the medicine works in the body indicates that peak concentrations are reached within approximately two to four hours after a dose. Consistent levels (known as steady-state concentrations) are typically achieved after about five days of continued, daily use. Official documentation indicates the full physiological response may develop over continued, long-term application.

Q: Is it normal to feel a bit tired when you first start taking Glocor?

Yes, fatigue (feeling tired) is classified in official documents as a common adverse reaction. Regulatory safety information notes that side effects like fatigue and tiredness are often experienced at the beginning of therapy. Official documentation indicates these symptoms are typically mild and may lessen or resolve within the first one to two weeks.

Q: Can Glocor be taken safely with common pain relievers like ibuprofen?

Regulatory documents state that co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes medicines like ibuprofen, may reduce the blood pressure lowering effect of Glocor. Official documents note that caution is exercised when considering this combination, particularly if used for long periods.

Q: If I miss a dose of Glocor, is there anything special I need to know?

Official regulatory guidance instructs that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely to ensure the regular dosing schedule is maintained.

Q: Can Glocor affect my ability to drive or operate machinery?

Glocor can affect alertness and coordination due to possible side effects such as dizziness, fatigue, or syncope (fainting). Regulatory warnings indicate that engaging in these activities should be avoided until the user is aware of how the medicine affects them.

Q: How is the action of Glocor different from similar medicines?

Glocor is classified as a cardioselective beta-blocker (beta1-antagonist), meaning it is specifically designed to act primarily on the beta1 receptors located mainly in the heart, helping to reduce the organ's workload. This contrasts with non-selective beta-blockers, which can affect other body systems more broadly.

Q: Do many people experience upset stomach as a side effect of Glocor?

Yes, regulatory documents classify Gastrointestinal Disorders as common adverse reactions. These include complaints such as nausea, vomiting, diarrhea, and abdominal pain, reflecting a higher frequency of occurrence among patients in clinical studies.

Q: Can Glocor be taken with food, or does it matter?

According to the official prescribing information, Glocor's absorption is not affected by food intake. Therefore, the medicine may be administered with or without a meal.

Q: Is Glocor safe for use in patients with kidney problems?

Regulatory documents restrict the use for patients with severe renal impairment, officially limiting the maximum daily dose to 10 mg. However, official documents indicate that a dose adjustment is typically not required for less severe impairment.

Q: Can Glocor cause problems with sleep (insomnia or drowsiness)?

Official documents list adverse reactions under Psychiatric disorders, which include reports of sleep disorders and insomnia (trouble sleeping) with Common or Uncommon frequency. Nightmares are also listed as a rare event.

Q: What kinds of studies support the use of Glocor?

Research supporting Glocor includes Phase II and III monotherapy trials (standalone treatment), combination therapy studies, and comparative studies. These investigations evaluated patient outcomes, safety profiles, and changes in symptom scores over varying periods, including follow-up for up to one year.

Q: What counts as a 'serious' side effect of Glocor according to regulatory bodies?

Official safety information defines a serious adverse reaction as an event that may result in death, hospitalization, persistent disability, or are otherwise life-threatening. Examples of these events include severe cardiovascular or hepatic (liver) events, which are defined in the Warnings and Precautions section of the official regulatory summary.

Q: Does Glocor cause weight gain, or is that a common myth?

Official adverse event reporting includes weight changes as a reported event under metabolic effects. The regulatory documentation reports this as an observed change but does not characterize weight gain as a common or guaranteed outcome.

Q: Why do official sources recommend regular monitoring when taking Glocor?

Official regulatory documents require regular monitoring during the initiation of treatment, especially for elderly patients and those with chronic heart failure. This is due to the need for cautious dose adjustment and the risks of serious adverse events associated with an abrupt stop to treatment.

Q: Is Glocor considered safe for use in older adults (seniors)?

Glocor is established for use in the adult population, and regulatory guidance states that no dosage adjustment is normally required for the elderly. However, official guidance suggests initiating treatment with the lowest possible dose and utilizing regular monitoring.

Q: Is there a generic version of Glocor available yet?

The medicine's active ingredient is Bisoprolol fumarate, which is widely recognized. This active ingredient is available in a generic formulation.

Q: How long does the effect of one dose of Glocor typically last?

The medicine has a relatively long elimination half-life of approximately 9 to 12 hours. This long duration of action supports its use in a once-daily dosing schedule.

Q: Is Glocor known to cause any significant mood changes?

Official documents list psychiatric adverse reactions including depression (Uncommon) and anxiety (Common). These events are formally documented as possible outcomes of treatment.

Q: Are there different forms or strengths of Glocor available?

Glocor is provided as a film-coated tablet for oral use and is available in multiple strengths to accommodate different conditions and dosage regimens. These available strengths include 1.25 mg, 2.5 mg, 5 mg, 10 mg, and 20 mg.

Q: Is Glocor likely to cause dryness of the mouth?

Official regulatory documents list dry mouth (xerostomia) as a reported adverse reaction under the autonomic nervous system effects.

Q: Can Glocor affect blood sugar levels?

Regulatory documents state that Glocor may interfere with the body's control of blood sugar levels. Official warnings also indicate that it may mask some symptoms of hypoglycemia (low blood sugar), such as a rapid heart rate, which is a key safety consideration for certain patients.

Q: Is Glocor safe to use if I have a history of heart issues?

While Glocor is used to treat specific heart conditions (hypertension, stable heart failure), official regulatory documents list several severe heart conditions that are officially designated as contraindications (conditions where the medicine should not be used). These include cardiogenic shock, third-degree AV block (without a pacemaker), and acute heart failure decompensation.

Q: If I'm taking other prescription drugs, what interaction categories should I be aware of with Glocor?

Regulatory documents outline interaction patterns including those causing Pharmacodynamic Synergy (which can increase the risk of severe low blood pressure), Clearance Modification (which can alter the medicine's effectiveness), and Pharmacodynamic Antagonism (which can reduce Glocor's blood pressure effect, as seen with NSAIDs).

How should Glocor be stored and disposed of?

The storage and disposal of Glocor (Bisoprolol fumarate) tablets must strictly follow official regulatory guidelines to maintain potency and safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
Protection Keep in the original container and keep it tightly closed to protect the tablets from moisture and light. Do not store in the bathroom.
Child Safety Keep this and all medicines out of the reach of children.

Disposal Instructions

Official guidelines state that unused or expired Glocor should be disposed of by taking it to a local medicine take-back program or collection site. Disposal by flushing down the toilet or pouring into wastewater is prohibited as per regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glocor found in:

A-Z Index: